Financhill
Sell
4

CLDI Quote, Financials, Valuation and Earnings

Last price:
$1.44
Seasonality move :
-22.96%
Day range:
$1.30 - $1.41
52-week range:
$0.73 - $18.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
432.5K
Avg. volume:
2.4M
1-year change:
-91.56%
Market cap:
$24.7M
Revenue:
--
EPS (TTM):
-$18.97

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLDI
Calidi Biotherapeutics
-- -$2.70 -- -50.03% --
ALUR
Allurion Technologies
$8.6M -$0.18 -32.4% -40.83% --
HROW
Harrow
$52.8M $0.07 61.72% -21.43% --
LUMO
Lumos Pharma
$253.3K -$0.90 545.07% -17.09% --
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLDI
Calidi Biotherapeutics
$1.41 -- $24.7M -- $0.00 0% --
ALUR
Allurion Technologies
$0.35 -- $22.4M -- $0.00 0% 0.52x
HROW
Harrow
$34.01 -- $1.2B -- $0.00 0% 7.15x
LUMO
Lumos Pharma
$3.05 -- $24.8M -- $0.00 0% 16.57x
NBY
NovaBay Pharmaceuticals
$0.52 -- $2.5M -- $0.00 0% 0.06x
PTN
Palatin Technologies
$0.97 -- $19M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLDI
Calidi Biotherapeutics
-- 7.007 -- --
ALUR
Allurion Technologies
-125.75% -4.301 91.46% 2.01x
HROW
Harrow
76.24% 4.555 11.62% 1.33x
LUMO
Lumos Pharma
-- -0.412 -- 2.11x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLDI
Calidi Biotherapeutics
-- -$5.2M -- -- -- -$5M
ALUR
Allurion Technologies
$3.1M -$12.3M -- -- -166.48% -$11.5M
HROW
Harrow
$37.2M $1.3M -13.44% -51.9% 2.69% $2.4M
LUMO
Lumos Pharma
-- -$7.6M -182.95% -182.95% -1052.34% -$5M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M

Calidi Biotherapeutics vs. Competitors

  • Which has Higher Returns CLDI or ALUR?

    Allurion Technologies has a net margin of -- compared to Calidi Biotherapeutics's net margin of -167.77%. Calidi Biotherapeutics's return on equity of -- beat Allurion Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.65 --
    ALUR
    Allurion Technologies
    57.97% -$0.14 -$28.7M
  • What do Analysts Say About CLDI or ALUR?

    Calidi Biotherapeutics has a consensus price target of --, signalling upside risk potential of 343.26%. On the other hand Allurion Technologies has an analysts' consensus of -- which suggests that it could grow by 428.19%. Given that Allurion Technologies has higher upside potential than Calidi Biotherapeutics, analysts believe Allurion Technologies is more attractive than Calidi Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    0 0 0
    ALUR
    Allurion Technologies
    0 0 0
  • Is CLDI or ALUR More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Allurion Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CLDI or ALUR?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allurion Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Allurion Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or ALUR?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Allurion Technologies quarterly revenues of $5.4M. Calidi Biotherapeutics's net income of -$5.1M is higher than Allurion Technologies's net income of -$9M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Allurion Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.52x for Allurion Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5.1M
    ALUR
    Allurion Technologies
    0.52x -- $5.4M -$9M
  • Which has Higher Returns CLDI or HROW?

    Harrow has a net margin of -- compared to Calidi Biotherapeutics's net margin of -8.57%. Calidi Biotherapeutics's return on equity of -- beat Harrow's return on equity of -51.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.65 --
    HROW
    Harrow
    75.6% -$0.12 $243.7M
  • What do Analysts Say About CLDI or HROW?

    Calidi Biotherapeutics has a consensus price target of --, signalling upside risk potential of 343.26%. On the other hand Harrow has an analysts' consensus of -- which suggests that it could grow by 75.98%. Given that Calidi Biotherapeutics has higher upside potential than Harrow, analysts believe Calidi Biotherapeutics is more attractive than Harrow.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    0 0 0
    HROW
    Harrow
    0 0 0
  • Is CLDI or HROW More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harrow has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.669%.

  • Which is a Better Dividend Stock CLDI or HROW?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Harrow pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or HROW?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Harrow quarterly revenues of $49.3M. Calidi Biotherapeutics's net income of -$5.1M is lower than Harrow's net income of -$4.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Harrow's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 7.15x for Harrow. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5.1M
    HROW
    Harrow
    7.15x -- $49.3M -$4.2M
  • Which has Higher Returns CLDI or LUMO?

    Lumos Pharma has a net margin of -- compared to Calidi Biotherapeutics's net margin of -1028.51%. Calidi Biotherapeutics's return on equity of -- beat Lumos Pharma's return on equity of -182.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.65 --
    LUMO
    Lumos Pharma
    -- -$0.90 $4.9M
  • What do Analysts Say About CLDI or LUMO?

    Calidi Biotherapeutics has a consensus price target of --, signalling upside risk potential of 343.26%. On the other hand Lumos Pharma has an analysts' consensus of -- which suggests that it could grow by 613.12%. Given that Lumos Pharma has higher upside potential than Calidi Biotherapeutics, analysts believe Lumos Pharma is more attractive than Calidi Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    0 0 0
    LUMO
    Lumos Pharma
    0 0 0
  • Is CLDI or LUMO More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lumos Pharma has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.76%.

  • Which is a Better Dividend Stock CLDI or LUMO?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lumos Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Lumos Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or LUMO?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Lumos Pharma quarterly revenues of $726K. Calidi Biotherapeutics's net income of -$5.1M is higher than Lumos Pharma's net income of -$7.5M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Lumos Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 16.57x for Lumos Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5.1M
    LUMO
    Lumos Pharma
    16.57x -- $726K -$7.5M
  • Which has Higher Returns CLDI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Calidi Biotherapeutics's net margin of -49.65%. Calidi Biotherapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.65 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CLDI or NBY?

    Calidi Biotherapeutics has a consensus price target of --, signalling upside risk potential of 343.26%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Calidi Biotherapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Calidi Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is CLDI or NBY More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock CLDI or NBY?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or NBY?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Calidi Biotherapeutics's net income of -$5.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5.1M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns CLDI or PTN?

    Palatin Technologies has a net margin of -- compared to Calidi Biotherapeutics's net margin of -2357.27%. Calidi Biotherapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLDI
    Calidi Biotherapeutics
    -- -$0.65 --
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About CLDI or PTN?

    Calidi Biotherapeutics has a consensus price target of --, signalling upside risk potential of 343.26%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Calidi Biotherapeutics, analysts believe Palatin Technologies is more attractive than Calidi Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLDI
    Calidi Biotherapeutics
    0 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CLDI or PTN More Risky?

    Calidi Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock CLDI or PTN?

    Calidi Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Calidi Biotherapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLDI or PTN?

    Calidi Biotherapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Calidi Biotherapeutics's net income of -$5.1M is higher than Palatin Technologies's net income of -$7.8M. Notably, Calidi Biotherapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Calidi Biotherapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLDI
    Calidi Biotherapeutics
    -- -- -- -$5.1M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
52
TSLL alert for Dec 24

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
73
PSIX alert for Dec 24

Power Solutions International [PSIX] is up 27.42% over the past day.

Sell
31
SOXL alert for Dec 24

Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock